{
    "nct_id": "NCT04840394",
    "official_title": "Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors",
    "inclusion_criteria": "Healthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Has disease that is suitable for local therapy administered with curative intent.\n2. Prior exposure to TLR7 agonists, TLR8 agonists, TLR 7/8 dual agonists, and TLR9 agonists.\n\nOther protocol defined inclusion/exclusion criteria could apply",
    "miscellaneous_criteria": "Inclusion Criteria\n\n1. Histologically or cytologically confirmed advanced or metastatic solid tumors that have disease progression after treatment with all available therapies for metastatic disease that are known to confer clinical benefit, or are intolerant to treatment, or refuse standard treatment. Note: there is no limit to the number of prior treatment regimens\n2. Evidence of progressive disease (PD) within 3 months of signing the informed consent form.\n3. Have measurable disease"
}